Two studies presented at IAS 2017 showed bictegravir to be very similar in efficacy to dolutegravir with slight differences in the formulations linked to the background NRTIs in the fixed-dose combinations.
Treatment Action Group's Richard Jefferys provides a comprehensive overview of HIV remission presentations at the 9th International AIDS Society Conference on HIV Science.
Reducing the number of drugs in a treatment regimen lowers long-term drug exposure and potential drug toxicity or drug interactions. What can we expect in the future for two-drug regimens?
Researchers found a higher set point viral load prior to antiretroviral treatment (ART) was associated with a larger HIV reservoir, while a longer duration of viral suppression due to ART was associated with a smaller reservoir.
Gilead Sciences has submitted a new drug application to the U.S. FDA for a single tablet fixed-dose combination of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF).
A medicine you get only every two months to reduce your risk of acquiring HIV could be an option in the future, but only if two clinical trials show that it is safe and effective.
This Week in HIV Research: New Maturation Inhibitor May Work Against Protease Inhibitor-Resistant HIV
This week, a study finds that a new maturation inhibitor in development, GSK3532795, shows activity against HIV that is resistant to protease inhibitors.
"Without early and consistent partnership with the community in our efforts to incrementally develop a cure for HIV we may never achieve what people with HIV most hope a cure will offer them."
A study showed that a new monoclonal antibody drug called ibalizumab reduced viral loads in individuals with multi-drug resistant HIV. Adding the drug to a failing regimen may help treatment-experienced people who have few options to control their vi...
An interview with Dan Barouch, M.D., Ph.D., on the key challenges in vaccine development, the pursuit of vaccines to potentially cure HIV and why we should be excited about antibodies.